Cite
HARVARD Citation
Razak, A. et al. (n.d.). A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors. European journal of cancer. pp. S21-S22. [Online].